Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses

• Status: Not yet recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

AGN-190584 has gone through many clinical trials showing its safety and effectiveness in individuals from 40-55 years of age. There has been no published data on the use of this product in individuals corrected with contact lenses for distance vision. There are many other applications AGN-190584 could be used for and further studies will show the effectiveness for each.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gordon Schanzlin New Vision
• Collaborator: AbbVie

Criteria

Inclusion Criteria:Presbyopic Subjects using single use, daily, contact lens for distance vision in both eyes, prescribed by the primary investigator. Lenses used will be Alcon dailies total one, Bausch+Lomb Infuse and Biotrue one day, Proclear one day, J&J Acuvue 1 day moist and 1 day Oasys.

Subjects from age 40-55 will be included in the investigation. Subjects will have spectacle prescriptions between -4.00D - +1.00D in power who are correctable to 20/25 or better for distance. Subjects will all be adapted contact lens wearers fit by the primary investigator. Subjects must be able to understand the consent agreement and willing to participate.

-

Exclusion Criteria: Non-contact lens wearers will be excluded. Previous use of AGN-190584 will be excluded as well as subjects above or below the age range stated in the inclusion criteria. Any corneal abnormality or eye pathology will be excluded that would affect the outcome in the investigator's opinion will be excluded. No patient with Iritis will be included. Any subject with known allergies to pilocarpine will be excluded.

-